Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
Clinical trial NCT07691333 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07691333
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2028-01-30
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.